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Forty years ago, the term “apoptosis” was introduced to describe a form of programmed cell death. Key players that mediate 
apoptosis at the molecular level such as caspases, death receptors, Bcl-2 family members have since been identified and their 
regulation remains a research focus of many laboratories. In 1993, approximately 20 years after the introduction of apoptosis, the 
sphingolipid ceramide was first linked to this form of cell death. Sphingolipids are bioactive components of cellular membranes that 
are involved in numerous physiological functions. In this paper, we discuss the inherent complexities of sphingolipid signaling and 
elaborate on how sphingolipids, primarily ceramide, influence apoptotic events such as death receptor aggregation in the plasma 
membrane and pore formation at the mitochondria. Possible roles of sphingolipids in other subcellular compartments, such as the 
nucleus, endoplasmic reticulum and lysosomes are also discussed. We conclude by summarizing the recent developments in sphin-
golipid based cancer therapy. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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HISTORICAL PERSPECTIVE
This year marks the ��th anniversary of the seminal 
pu�lication �y Kerr� Wyllie and Currie in the British 
Journal of Cancer in which the term “apoptosis” was 
introduced to descri�e a form of programmed cell 
death [�]. In the Greek language “apoptosis” means 
“dropping off” of leaves from trees or petals from flow-
ers. The British scientists used the term for the mor-
phological description of �le�s that are pinched of the 
cell as it undergoes programmed cell death. Apoptosis 
is a carefully controlled signaling cascade that can 
�e initiated through extrinsic signals or intrinsic stress. 
Although key players of apoptosis such as death re-
ceptors� caspases� and Bcl-� family mem�ers have 
�een identified� their regulation remains under intense 
investigation. This review focuses on the influence 
of sphingolipid signaling on apoptotic cell death.
�phingolipids were first descri�ed �y the German 
�iochemist� J.L.W. Thudichum in �88�. For approxi-
mately ��� years sphingolipids were thought to function 
merely as structural components of cellular mem�ranes. 
In �99�� a seminal paper pu�lished �y the la�ora-
tory of Yusuf Hannun linked the sphingolipid ceramide 
to apoptosis [�]. Prompted �y the o�servation that TNF 
treatment of U9�7 leukemia cells resulted in hydrolysis 
of sphingomyelin and generation of ceramide� they in-
vestigated whether ceramide itself can induce apoptosis. 
Indeed� exogenous ceramide �ut not other amphipathic 
lipids or structurally similar dihydro-ceramide induced 
DNA laddering� a classical hallmark of apoptosis. Other 
la�oratories su�sequently demonstrated a role for ce-
ramide in response to various apoptotic stimuli in cells 
derived from diverse tissues [��8]. �phingolipid signal-
ing has now taken center stage as cloning of enzymes� 
development of tools to study their roles� and methods 
of detection� have permitted insights into the complexity 
of sphingolipid �iology. 
THE COMPLEXITY OF SPHINGOLIPID 
SIGNALING
�phingolipids have �een shown to modulate 
apoptosis at multiple steps of the process� including 
clustering of cell surface receptors and involvement 
in permea�ilization of the outer mitochondrial mem-
�rane. Here we will review the complexity of sphingolipid 
signaling and elucidate the role of meta�olic enzymes 
and sphingolipids in various su�cellular compartments 
in relationship to apoptotic signaling. Three main levels 
of complexity have to �e considered when discussing 
sphingolipid signaling. First� a large variety of sphingo-
lipids with diverse signaling capa�ilities can �e gener-
ated �y su�strate utilization and modification of the 
sphingoid �ack�one. �econd� numerous sphingolipid 
enzymes and enzyme families catalyzing opposing �io-
chemical reactions function to maintain homeostasis 
�y interconverting different sphingolipids. Finally� 
sphingolipid meta�olism is highly compartmentalized.
Sphingolipid variety
Mammalian sphingolipids have an �8-car�on chain 
sphingoid �ack�one attached to a head group and are 
conjugated to an acyl group of varying car�on chain 
length [9]. Ceramide is the �asic unit of sphingolipids 
that contains a sphingosine �ack�one� a fatty acid side 
chain and a hydrogen atom as the head group. Variety 
is achieved �y incorporation of fatty acids that differ 
in chain length and su�stitutions in the head group. 
The activity of a “ceramide synthase” had �een 
descri�ed �iochemically �ut it was not until the early 
����’s that a family of six enzymes with preferential su�-
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strate specificity was identified at the genetic level [��� 
��]. These ceramide synthases� also initially descri�ed 
as “LA��” for longevity assurance genes� generate 
ceramides with fatty acids ranging from �� to �6 car-
�ons. For example� ceramide with a �6-car�on fatty 
acid is known as C�6-ceramide� whereas incorporation 
of an �8-car�on fatty acid yields C�8-ceramide. The 
increased use of liquid chromatography-mass spec-
troscopy �LC-M�� to determine changes in specific ce-
ramide species reveals that generation of C�6-ceramide 
may�e preferentially associated with apoptosis. �tudies 
from the Amascato la�oratory demonstrated that ex-
posure of cells to FasL or radiation induced a specific 
increase in mitochondrial C�6-ceramide that closely 
paralleled the decrease in mitochondrial mass during 
apoptosis [��� ��]. Krosen and co-workers showed that 
crosslinking of the B-cell receptor results in increased 
C�6- �ut not C��-ceramide during early apoptosis [��]. 
�imilarly� we detected a preferential increase in C�6-
ceramide during TRAIL-mediated apoptosis in sensitive 
�ut not resistant cells [�5]. Recently� C�6-ceramide was 
linked to triacylglycerol-induced apoptosis in macro-
phages [�6]. In addition to C�6-ceramide� C�8-ceramide 
is also important for apoptosis. The Ogretmen la�ora-
tory found that head and neck squamous cancer cells 
have a selective decrease in C�8-ceramide and that 
restoration to normal levels �y overexpression of murine 
ceramide synthase � �Cer��� resulted in modulation 
of telomerase activity and induction of apoptosis resul-
ting in 7��8�% growth inhi�ition [�7]. C�8-ceramide may 
also contri�ute to amyloid protein mediated apoptosis 
in neuronal cells in Alzheimer’s disease [�8]. In contrast� 
growth arrest may �e more specifically associated with 
an increase in C��-ceramide [�9]. Taken together� these 
studies indicate that cellular responses can �e influ-
enced �y changes in specific ceramide species.
�u�stitution of different head groups yields complex 
sphingolipids. For example� replacing the hydrogen 
head group with phosphocholine yields sphingomy-
elin� whereas su�stitution with sugars leads to genera-
tion of glycosphingolipids. �ince these su�stitutions 
can occur on ceramides with different fatty acid chain 
lengths� sphingomyelin species also exist as C�6-�M� 
C�8-�M� C��-�M etc. �phingolipids can also �e modi-
fied �y phosphorylation. The com�ination of different 
fatty acids with head group su�stitution and further 
modification such as phosphorylation� yields a large 
num�er of sphingolipids that each may have its own 
importance in cell physiology. According to the LIPID 
MAP� structure data�ase� nearly ���� different sphin-
golipids that occur naturally in organisms from yeast 
to mammals as well as those generated synthetically 
have �een descri�ed �http://www.lipidmaps.org/data/ 
structure/index.html�.
Metabolic flux
�econd� sphingolipid meta�olic enzymes function 
as a family to maintain homeostasis. Ceramide is con-
sidered the “hu�” of sphingolipid meta�olism and can 
�e generated �y multiple pathways. The entry point into 
sphingolipid meta�olism is the condensation serine 
palmitoyl transferase� which catalyses the condensation 
of serine and palmitoyl CoA. The pro duct is reduced� 
acylated and desaturated to gene rate ceramide via the 
de novo pathway. Alternatively� ceramide can �e gen-
erated from hydrolysis of complex sphingolipids. For 
example� cleavage of sphingomyelin �y sphingomy-
elinases results in phosphatidylcholine and ceramide. 
Lastly� sphingosine can �e utilized �y ceramide syn-
thases to generate ceramide via a salvage pathway. Just 
as ceramide can �e generated �y multiple mechanisms� 
it can also �e cleared �y se veral meta�olizing enzymes� 
including sphingomyelin synthases and ceramidases. 
�phingosine� the product of ceramidase action� serves 
as a su�strate for sphingosine kinase to generate 
sphingosine-�-phosphate ���P�. Hydrolysis of ��P 
into ethanolamine phosphate and hexadecenal �y ��P 
lyase is the only route to exit sphingolipid meta�olism. 
Virtually all meta�olic reactions �etween entry and 
exit points of sphingolipid meta�olism are intercon-
verti�le [9]. Consequently� sphingolipid meta�olism 
is in constant flux with the �alance �etween pro- and 
anti-apoptotic meta�olites determining cellular fate. 
Over the last �� years� this concept has �ecome known 
as the “sphingolipid rheostat” [��� ��]. The meta�olites 
ceramide and sphingosine have �een associated with 
apoptosis� cell cycle arrest� senescence and differentia-
tion whereas ��P plays an important role in suppression 
of apoptosis� survival� angiogenesis and inflamma-
tion. A simplified sphingolipid pathway and rheostat 
are shown in Fig. �. A shift of sphingolipid meta�olism 
�or the rheostat� towards increased production of ce-
ramide is anti-proliferative while a shift towards ��P fa-
vors survival [��]. Thus enzymes participating in sphin-
golipid meta�olism form an intricate network to maintain 
homeostasis and to dictate cellular physiology. 
Fig. 1. �phingolipid meta�olism and homeostasis. Ceramide 
is synthesized de novo and can also �e generated through 
�reakdown of complex sphingolipids. Ceramide can also �e fur-
ther meta�olized to sphingosine� which is then phosphorylated 
to generate ��P. Degradation of ��P �y ��P lyase marks the 
exit from sphingolipid pathway. Ceramide has �een linked 
to anti-proliferative responses including apoptosis while ��P 
is important for survival. Homeostasis is maintained through 
interconversion of ceramide and ��P though sphingosine. Ab-
breviations used: �Mase — sphingomyelinase� �M� — sphingo-
myelin synthase� Cer� — ceramide synthase� �K — sphingosine 
kinase� �PP — sphingosine-�-phosphate phosphatase� ��P 
lyase — sphingosine-�-phosphate lyase
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Compartmentalization
Compartmentalization of sphingolipid meta�oliz-
ing enzymes into different su�cellular locations adds 
a third dimension of complexity. De novo ceramide 
generation occurs at the endoplasmic reticulum and 
is followed �y modification to glycosphingolipids and 
sphingomyelin in the Golgi network. The ceramide 
transporter CERT shuttles ceramide from the endo-
plasmic reticulum to sphingomyelin synthase � in the 
Golgi for synthesis of sphingomyelin [��]. CERT is highly 
specific for ceramide [��] �ut it is not yet known whether 
CERT transfers ceramide to su�cellular locations other 
than the Golgi or whether additional ceramide transport 
proteins exist. Once incorporated into complex sphin-
golipids within cellular mem�ranes� ceramide can �e li�-
erated �y hydrolysis �ut its range of activity is locally 
restricted �y its hydropho�ic nature. Only sphingosine 
is solu�le and can �e recycled via the salvage pathway 
to regenerate ceramide in other cellular compartments. 
Thus sphingolipid enzymes and products are largely 
restricted to act at the site of generation and different 
pools of ceramides may �e important for specific func-
tions in certain su�cellular compartments. 
SPHINGOLIPID-MEDIATED REGULATION 
OF APOPTOSIS PROXIMAL TO THE 
PLASMA MEMBRANE
Apoptosis can �e initiated through extracellular 
stress� which involves propagation of an extrinsic stimu-
lus such as �inding of a ligand �FasL� TNF� TRAIL� to their 
respective death receptors on the cell surface. Alterna-
tively� extrinsic apoptosis can �e initiated through de-
pendence receptors �i.e. netin receptors� when ligands 
fall �elow a critical threshold [�5]. Death receptors are 
found in the plasma mem�rane� where they likely exist 
as timers in so-called pre-ligand assem�ly domains 
[�6]. Ligand �inding results in receptor sta�ilization 
and conformational changes in its cytoplasmic domain 
to permit �inding of intracellular signaling molecules. 
In FasL and TRAIL-mediated apoptosis� the adaptor pro-
tein FADD and pro-caspase-8 �-��� are recruited to form 
the death inducing signaling complex �DI�C� in which 
caspase-8 is cleaved into an active tetramer. In TNF-
mediated apoptosis� caspase-8 is activated in a two-step 
manner via complex I �TNF-R�/RIP�/TRAF�/TRADD� 
and complex II �RIP�/TRAF�/TRADD/FADD/caspase-8�.
�phingolipids have important roles in initial apop-
totic events at the plasma mem�rane. According 
to the classic fluid mosaic model that was proposed 
�y �inger and Nicolson phospholipids and proteins 
were uniformly distri�uted in mem�ranes [�7]. How-
ever� �imons and Ikonen su�sequently suggested the 
presence of specific structures called lipid rafts that 
are enriched in sphingolipids [�8]. Indeed� ceramide 
has �een shown to increase rapidly following engage-
ment of surface Fas� suggesting that it was li�erated 
�y activation of sphingomyelinases. �everal sphingo-
myelinases exist in mammals including acid sphingo-
myelinase �A�M� and three neutral sphingomyelinases 
�N�M�� N�M� and N�M��. Both A�M and N�M� have 
�een linked to apoptosis [�9� ��]. Ceramide generated 
at the plasma mem�rane following A�M-mediated 
hydrolysis of sphingomyelin is thought to �e instru-
mental in reorganization of signaling molecules into 
ceramide-enriched platforms. 
Acid sphingomyelinase
Acid sphingomyelinase �A�M� is an enzyme lo-
cated within the lysosomal/endosomal compartment 
whose lack of function was initially known to cause 
the lysosomal storage disorder Niemann-Pick disease 
[��]. Joint efforts of several research groups have 
esta�lished A�M as an important stress activated 
enzyme following ligation of death receptors as well 
as non-receptor stimuli [�9]. A�M acts on sphin-
gomyelin to li�erate ceramide �y cleavage of the 
phosphocholine head group. A role for A�M in apop-
tosis was discovered when cells from Niemann-Pick 
patients were evaluated for radiation responsiveness. 
Interestingly� Niemann-Pick lympho�lasts resisted 
radiation-induced apoptosis� a phenotype that was 
reversi�le upon restoration of A�M expression [��]. 
Mouse em�ryo fi�ro�lasts from A�M-deficient mice 
were also resistant to radiation-induced apoptosis 
and partially resistant to TNF or serum withdrawal 
induced apoptosis [��]. In a model of Fas-induced 
apoptosis� ceramide generation was attri�uted to ac-
tivation of �oth neutral and acid sphingomyelinase� yet 
only A�M activation was linked to propagation of the 
apoptosis signal [��]. Taken together� these studies 
clearly defined a role for A�M in apoptosis.
ASM-mediated formation of ceramide-en-
riched platforms
An important early event at the plasma mem�rane 
following initiation of death receptor mediated apopto-
sis involves clustering of the receptors. Cremesti et al. 
demonstrated rapid formation of receptor signaling 
platforms into “caps” following stimulation of Fas. 
This event was A�M-dependent and a defect in “cap” 
formation could �e overcome �y providing cells with 
exogenous C�6-ceramide [�5]. Grassme and Gul�ins 
first proposed a model in which A�M translocates 
to the plasma mem�rane� flips to the outer side of the 
cell and hydrolyzes sphingomyelin in the outer leaflet 
of the mem�rane to generate ceramide� which then fa-
cilitates clustering of receptors into signaling platforms 
[�6]. �everal studies have shown that A�M activation 
following stimulation of Fas is dependent on the activity 
of the initiator caspase-8 and that ceramide functions 
to amplify caspase-8 activity [�7��9]. In contrast� 
radiation-induced apoptosis was independent of cas-
pase activation [�9]. Although initial studies were con-
ducted in models that involved stimulation of Fas� it was 
su�sequently shown that chemotherapeutic agents� 
including doxoru�icin and cisplatin� also activate A�M 
and facilitate death receptor-mediated apoptosis [��� 
��]. Both Fas and the related death receptor ligand 
TRAIL activate A�M via a redox dependent mechanism 
[��]� suggesting the possi�ility that induction of oxida-
tive stress� common to �oth chemotherapy and death 
receptor-mediated apoptosis� may �e involved in this 
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process. However� the exact mechanism �y which 
non-receptor ligands induce ceramide-rich signaling 
platforms within plasma mem�ranes remains unclear. 
How does an enzyme� which is primarily located 
in the lysosomal compartment with optimal function 
at an acidic pH� hydrolyze sphingomyelin in the outer 
leaflet of the plasma mem�rane? While earlier studies 
employing immunohistochemistry demonstrated that 
A�M relocates to the plasma mem�rane in response 
to stress stimuli� a mechanism was eluded only recently. 
Using a UV stress model� Zeidan et al. demonstrated that 
PKC-mediated phosphorylation of A�M on �er5�8 was 
required for translocation of A�M to the plasma mem-
�rane [��]. A recent study confirmed a role for PKC 
in translocation of A�M to the plasma mem�rane. 
Tsukamoto and coworkers found that phosphorylation 
of PKC on �er66� was required for A�M translocation 
to the plasma mem�rane of multiple myeloma cells that 
had �een exposed to the green tea polyphenol EGCG 
[��]. While generation of ceramide was not determined� 
it may have contri�uted to lipid raft clustering of the lam-
inin receptor there�y promoting apoptosis [��]. While 
A�M is partially active at neutral pH [�5]� the possi�ility 
that phosphorylation improves activity at physiological 
pH has not yet �een investigated. 
Although several investigators demonstrated that 
A�M plays an important role in apoptosis� its activity 
is not universally required. For example� A�M-deficient 
cells can still undergo staurosporine-induced apopto-
sis� which is independent of ceramide formation [��]. 
In addition� the Blitterswijk group found that ceramide 
generation upon Fas stimulation occurs within hours 
rather than minutes and is independent of A�M [�6� 
�7]. Our la�oratory has studied ceramide generation 
in response to TRAIL using the isogenic colon can-
cer cell lines �W�8� and �W6��� which are TRAIL 
sensitive and resistant� respectively. �imilar to the 
Blitterswijk group� we were una�le to detect a rapid 
increase in ceramide generation� although ceramide 
did increase at later time points paralleling caspase ac-
tivation [�5]. In our hands� clustering of TRAIL receptor 
� �DR5� correlated with apoptotic suscepti�ility in the 
�W�8�/�W6�� model �ut disruption �y pretreatment 
with nystatin did not impact effector caspase activity 
in �W�8� cells �White-Gil�ertson and Voelkel-John-
son� unpu�lished data�. These results suggest that 
the requirement for A�M in apoptosis may �e stimulus 
and cell type-specific. The o�servation that apoptosis 
resistance in A�M-deficient cells can �e overcome 
�y exogenous ceramide� suggests that ceramide� not 
necessarily A�M� it critical for apoptosis [��].
SPHINGOLIPID-MEDIATED REGULATION 
OF APOPTOSIS AT THE MITOCHONDRIA
Mitochondria play a central role in the extrinsic 
as well as intrinsic pathway of apoptosis. In extrinsic 
apoptosis� mitochondrial events serve as an amplifica-
tion loop. Caspase-8� activated in response to death 
receptor ligands� not only cleaves downstream ex-
ecutioner caspases �ut also Bid� a pro-apoptotic 
BH�-only protein of the Bcl-� family. Truncated Bid 
facilitates oligomerization of Bax �and/or Bak� leading 
to pore formation� permea�ilization of the outer mito-
chondrial mem�rane� and leakage of proteins such 
as cytochrome c� �MAC/Dia�lo� and AIF� and other 
apoptogenic factors into the cytosol. Cytochrome c to-
gether with pro-caspase-9 and Apaf-� forms the apop-
tosome� the complex in which caspase-9 is activated 
to cleave the executioner caspase-�. �MAC/Dia�lo 
relieves the inhi�itory function of IAP’s on executioner 
caspases and AIF translocates to the nucleus where 
it is involved in DNA fragmentation [�8]. These post-
mitochondrial events are also initiated when stressors 
such as chemotherapeutic agents or radiation trigger 
apoptosis intrinsically� except that BH�-only proteins 
other than Bid promote Bax �or Bak� mediated pore 
formation in the outer mitochondrial mem�rane [�9].
Ceramide plays an important role in these mi-
tochondrial events. Zhang et al. demonstrated that 
hydrolysis of �M and generation of ceramide following 
TNF stimulation occurs in a compartment distinct from 
the plasma mem�rane [5�]. In support� transfection 
of �ut not exogenous treatment with �acterial �Mase 
recapitulated ceramide-mediated apoptosis� indicating 
that intracellular ceramide generation is required for the 
response. In a su�sequent study� targeted expression 
of �acterial �Mase resulted in elevated ceramide levels 
in the respective su�cellular compartments� yet apop-
tosis occurred only when �acterial �Mase was targeted 
to the mitochondria [5�]. Mitochondrial ceramide plays 
an important role in Bax oligomer formation following 
exposure to TNF [5�]. Importantly� ceramide and Bax 
synergize to induce permea�ilization of the outer mito-
chondrial mem�rane [5�].
Ceramide may facilitate apoptosis via formation 
of channels in the mitochondrial mem�rane. Mark 
Colum�ini’s group first demonstrated the forma-
tion of ceramide channels in cell-free phospholipid 
mem�ranes [5�] and su�sequently confirmed these 
results in isolated rat liver mitochondria [55]. Ce-
ramide channels permitted the release of proteins 
smaller than 6�kDa� such as cytochrome c� from the 
intermem�rane space of the mitochondria [55]. Of sig-
nificance is that ceramide channel formation appears 
to �e unique to the outer mitochondrial mem�rane and 
occurs in response to ceramide concentrations that are 
physiologically relevant [56]. Furthermore� the forma-
tion of these channels is a regulated process� since 
disassem�ly can occur �y the action of anti-apoptotic 
proteins like Bcl-xL [57] and since channel formation 
in isolated mitochondria and liposomes can �e inhi�-
ited �y the sphingolipid dihydro-ceramide� which until 
recently had �een �elieved to �e �iologically inactive 
[58]. Lastly� while the ceramide meta�olite sphingosine 
can also form channels in isolated mitochondria� these 
channels are smaller than those formed �y ceramide� 
and do not allow passage of pro-apoptotic proteins 
out of the mitochondria [59]. In fact� sphingosine 
may also play a role in disassem�ly of ceramide chan-
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nels� suggesting the existence of a positive feed�ack 
mechanism that regulates ceramide channels [6�].
The source of mitochondrial ceramide is largely 
unknown� �ut several enzymes involved in sphingolipid 
meta�olism are localized to the mitochondria and may 
play a role in generation of a local pool of ceramide 
that facilitates apoptosis. For instance� the Gudz 
group showed that Cer�� and Cer�6 partially localize 
to the �rain mitochondria upon ischemia reperfusion 
injury and elevate C�8- and C�6-ceramides respec-
tively [6�]. The Kolesnick group descri�ed mitochon-
drial ceramide-rich macrodomains that are sensitive 
to ceramide synthase inhi�ition and are involved in Bax 
mem�rane insertion and mitochondrial apoptosis 
in HeLa cells [6�]. While providing the ceramide syn-
thase su�strate sphingosine to isolated mitochondria 
resulted in ceramide generation� this response was not 
impacted �y the ceramide synthase inhi�itor fumonisin 
B� �ut was partially �locked �y ceramidase inhi�ition 
[59]. A later study found that mitochondria from neu-
tral ceramidase knockout mice had a reduced a�ility 
to generate ceramide from sphingosine implicating 
that the reverse activity of this enzyme contri�utes 
to mitochondrial ceramide generation [6�]. Recently� 
Wu et al. characterized a novel mitochondria associated 
neutral sphingomyelinase [6�] �ut whether this enzyme 
contri�utes to apoptosis has not yet �een investigated.
SPHINGOLIPIDS AND NUCLEAR 
APOPTOTIC EVENTS
�phingomyelin is present not only in the plasma 
mem�rane �ut also in the nuclear envelope and intra-
nuclear sites. �everal la�oratories have demonstrated 
a role for nuclear ceramide in apoptosis. Tsugane and 
co-workers found that hepatocyte apoptosis following 
portal vein ligation in an in vivo model was preceded 
�y an increase in neutral sphingomyelinase �N�M� 
activity and su�sequent generation of ceramide and 
sphingosine [65]. A French group found that ionizing 
radiation failed to induce ceramide generation in nuclei-
free lysates and cytoplasts� although cytoplasts did 
respond to Fas �y externalization of phosphatidylserine 
[66]. Activation of N�M� ceramide generation and fea-
tures of apoptosis� such as PARP and DNA cleavage� 
were o�served in highly purified nuclei [66]. Watana�e 
et al. found that Fas stimulation of Jurkat T cells resulted 
in increased nuclear ceramide though the activation 
of a putative nuclear N�M and inhi�ition of sphingo-
myelin synthase ��M�� [67]. The caspase-� inhi�itor� 
Ac-YVAD-cmk� prevented Fas-induced apoptosis� 
generation of ceramide and stimulation of N�M acti-
vity� suggesting that these events occur downstream 
of executioner caspase activation [67]. �imilarly� serum 
deprivation of hippocampal cells resulted in activation 
of a putative nuclear N�M and inhi�ition of �M� [68]. 
�timulation of N�M� inhi�ition of �M� and increased 
ceramide is also o�served in response to radiation 
of nuclei isolated from proliferating cells [69]. Taken 
together� these studies suggest activation of a nuclear 
N�M and generation of nuclear ceramide play an impor-
tant role in a variety of apoptosis models. However� the 
role of nuclear ceramide in apoptosis remains to �e ad-
dressed. One possi�ility is that ceramide affects nucleo-
cytoplasmic trafficking.
Numerous proteins translocated to and from the 
nucleus during apoptosis. One of the hallmarks dur-
ing apoptosis is DNA fragmentation� which is medi-
ated �y AIF� EndoG and CAD [7�� 7�]. These proteins 
translocate from the mitochondria to the nucleus 
�AIF� EndoG� or are activated �y caspase-mediated 
cleavage of an inhi�itory unit �CAD�. Other proteins 
that enter the nucleus during apoptosis include mi-
tochondrial proteins �AIF� WOX�� EndoG� and death-
fold proteins� which are directly or indirectly involved 
in caspase activation �DEDD� TRADD� FADD� Apaf-�� 
PEA-�5� [7�� 7�]. Proteins that are released from the 
nucleus during apoptosis include p5�� which interacts 
with Bcl-� at the mitochondria and histone H�.�� which 
appears to �e involved in oligomerization of Bax at the 
mitochondria [7�]. Nucleo-cytoplasmic exchange oc-
curs through nuclear pore complexes �NPC�� which 
consist of a�out �� different proteins that make up the 
cytoplasmic fi�rils� the central framework and the 
nuclear �asket [7�]. Of the �8 nucleoporins in the NPC 
only 7 are caspase su�strates [75]. Passive transport 
into the nucleus is restricted to small molecules and 
timing of nucleoporin degradation suggests that active 
transport is required for exchange of proteins �etween 
the nucleus and the cytoplasm during apoptosis. For 
example� active caspase-� is found in the nucleus 
during apoptosis and is transported into the nucleus 
�y a specific �ut yet unidentified mechanism [76]. A-
kinase-anchoring protein 95 �AKAP95� has �een iden-
tified as a potential carrier of active caspase-� [77]. 
Faustino and co-workers recently addressed the 
hypothesis that ceramide inhi�its cell growth �y im-
pacting nucleo-cytoplasmic trafficking and demon-
strated that treatment of vascular smooth muscle 
cells with exogenous ceramide altered the distri�ution 
of importin-α and the RanGTP �ound exportin Cellular 
Apoptosis �uscepti�ility �CA�� protein via a p�8-medi-
ated mechanism [78]. Whether endogenous ceramide 
induces similar changes has not yet �een investigated. 
Additionally� it is not yet known whether ceramide af-
fects the redistri�ution of proteins involved in nucleo-
cytoplasmic transport during apoptosis and whether 
a nuclear pool of ceramide specifically contri�utes 
to these events. It has �een esta�lished that nucleo-
cytoplasmic transport is affected at an early stage 
of apoptosis independent of caspase activity. The 
redistri�ution of Ran� importin-α and importin-β upon 
induction of apoptosis occurs in the a�sence or pres-
ence of the pan-caspase inhi�itor ZVAD [79]. Cyto-
plasmic Ran also accumulates in response to cispla-
tin� hydrogen peroxide� and UV irradiation and may 
represent a general early event during apoptosis [8�]. 
Permea�ility to larger size dextrans increases during 
this phase of apoptosis �ut the mechanism mediating 
increased NPC permea�ility is unknown [8�]. Given 
that ceramide can influence the �ehavior of proteins 
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in the plasma mem�rane and contri�utes to the for-
mation of mitochondrial channel formation during 
apoptosis� it is tempting to speculate that ceramide 
may also play a role in the dilation of the NPC. 
SPHINGOLIPID-MEDIATED REGULATION 
OF APOPTOSIS IN OTHER SUBCELLULAR 
COMPARTMENTS
�o far we have discussed the role of ceramide in ag-
gregation of death receptors into signaling platforms 
at the plasma mem�rane� in channel formation of the out-
er mitochondrial mem�rane� and the existence of a puta-
tive sphingomyelin cycle in the nucleus. However� other 
compartments such as the lysosomes and endoplasmic 
reticulum are also involved in apoptosis and some links 
to sphingolipid meta�olism have �een esta�lished.
Lysosomes
In �998� Monney and co-workers reported that an 
“acidic compartment” contri�utes to TNF-induced 
apoptosis [8�]. It was su�sequently shown that the 
ceramide meta�olite sphingosine is lysosomotrophic 
and its accumulation in the lysosome results in partial 
rupture prior to caspase activation and loss of mito-
chondrial function [8�]. Lysomotropic acid ceramidase 
inhi�itors have also �een shown to induce apoptosis 
�y modulating ceramide meta�olism [8�]. Cathepsin 
D� an aspartic protease found in the lysosome that can 
contri�ute to death receptor mediated apoptosis� has 
�een identified as a direct target of ceramide� which 
is generated following activation of A�M [8�� 85]. 
As discussed a�ove� chemotherapeutic agents can 
mediate apoptosis via an A�M/ceramide-dependent 
pathway. Dumitru et al. demonstrated that clinically rel-
evant concentrations of gemcita�ine induced apopto-
sis in glioma cells via activation of A�M� which resulted 
in lysosomal accumulation of ceramide� activation 
of cathepsin D and insertion of Bax into the mitochon-
drial mem�rane ultimately leading to cell death [86]. 
Camptothecin-mediated apoptosis in U9�7 myeloma 
cells was mediated �y activation of PKC∆� which trans-
located to the lysosomal compartment to phosphory-
late and stimulate the activity of A�M [87]. In summary� 
�oth extrinsic and intrinsic apoptotic pathways have 
�een linked to lysosomal sphingolipid meta�olism.
Endoplasmic reticulum (ER)
�tress caused �y changes in cellular ATP� redox 
states or calcium concentration results in reduced 
a�ility of the ER to chaperone protein folding� there�y 
activating the Unfolded Protein Response �UPR� [88]. 
Prolonged UPR may trigger apoptosis via three different 
signaling pathways� involving inositol-requiring pro-
tein �α �IRE�α�� protein kinase RNA-like endoplasmic 
reticulum kinase �PERK� and activating transcription 
factor 6 �ATF6� [89]. These may activate caspases di-
rectly or through activation of mitochondrial apoptosis 
[88� 9��9�]. �ince de novo ceramide synthesis takes 
place in the ER links �etween sphingolipid meta�olism 
and ER stress-induced apoptosis have �een explored. 
Ceramide synthases are ER resident enzymes 
involved in the de novo pathway of sphingolipid me-
ta�olism. �everal studies indicate a possi�le role for 
Cer�6 in ER stress. For example� in renal cancer cells� 
MDA7/IL-�� induced apoptosis via a Fas-mediated 
mechanism that was dependent on the expression 
of Cer�6 [9�]. Ceramide plays an important role 
in MDA7/IL-�� induced apoptosis and may mediate its 
effects via interaction with Beclin � as well as calpain-
mediated cleavage of ATF5� there�y switching the 
physiological response from autophagy and to apopto-
sis [9�� 95]. Another study demonstrated that geldana-
mycin ��7AAG� results in loss of GRP78/BiP function and 
induced de novo ceramide synthesis [96]. Cer�6 was 
implicated in this response� since �W6�� colon cancer 
cells overexpressing the enzyme were more suscepti�le 
to �7AAG than control cells [96]. Cer�6 may also con-
tri�ute to apoptosis in yeast and rat pancreatic IN�-�E 
cells in which activation of the UPR resulted in tran-
scriptional activation of Cer�6 and generation of C�6-
ceramide [97]. On the other hand� in squamous cell 
carcinoma cells downregulation of Cer�6/C�6-ceramide 
was required to enhance ER stress induced apoptosis 
via activation of ATF6 activation [98]. Thus contri�u-
tion of Cer�6 activity towards ER stress and apoptosis 
may �e context-specific. �tudies in HEK�9� cells 
indicate that Cer��� which preferentially generates 
C�8-ceramides� translocates from the ER to the Golgi 
following treatment with cisplatin [99] while apoptosis 
in response to serum starvation increased the propor-
tion of the pro-apoptotic sphingosine kinase � in the 
ER [���]. Therefore� apoptotic stimuli not only affect 
the activity of sphingolipid enzymes �ut can also alter 
their distri�ution to and from the ER.
INDUCTION OF APOPTOSIS 
BY MODULATING SPHINGOLIPIDS 
IN CANCER THERAPY
�trategies to eliminate malignant cells typically in-
duce apoptosis via the intrinsic or extrinsic pathway and 
frequently impact sphingolipid meta�olism. Whether 
sphingolipid meta�olism is targeted intentionally 
through recently designed sphingolipid analogs and 
anti�odies or whether it is impacted �y radiation and 
chemotherapy� a shift in the sphingolipid rheostat to-
wards increased ceramide and decreased ��P is a com-
mon denominator. We have summarized therapies 
that increase apoptosis through promoting ceramide 
generation� inhi�iting ceramide clearance� or interfering 
with ��P generation and signaling �see Ta�le�.
Stimulation of ceramide synthesis
Ceramide can �e generated through increased 
ceramide synthesis or �reakdown of complex sphin-
golipids. In many models� the apoptotic response 
is sensitive to inhi�ition �y myriocin and/or fumonisin 
B�� indicating a requirement for the activity of �PT 
and/or Cer� [�������]. Of the ceramide synthases� 
Cer�� and Cer�6 have �een primarily associated 
with apoptosis [������8]. �trategies that facilitate 
the �reakdown of sphingomyelin into ceramide via 
sphingomyelinase activation include radiation and 
well-known chemotherapeutics such as cisplatin and 
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camptothecin [�� ��� 87]. More recently� naturally 
occurring compounds such as the plant extract evodi-
amine� capsaicin an active component of chili peppers� 
the green tea extract EGCG� the vitamin E derivative 
α-TEA and cyclopamine� a naturally occurring alkaloid 
that inhi�its hedgehog signaling were found to pro-
mote apoptosis via sphingomyelinase activity [��� 
��9����]. MDA7/IL-�� requires �oth Cer�6 and A�M 
for induction of apoptosis in prostate and renal cell 
carcinoma cell lines [9�� ���] and has shown efficacy 
against renal cell tumor growth in vivo [���].
Inhibition of ceramide metabolism
Intracellular ceramide may also �e increased 
through prevention of su�sequent meta�olic conversion 
into sphingosine and ��P or into complex sphingolip-
ids. Development of ceramide analogs that interfere 
with acid ceramidase have �een the most prominent 
approach. The prototype drug B�� effectively inhi�ited 
the growth of hepatic cancer xenografts [��5]� there�y 
prompting further modification and design of this drug 
[��6���8]. B��-�ased drugs have �een successfully 
com�ined with apoptin and FasL gene therapy in pre-
clinical models of prostate and head and neck cancers 
[��9� ���]. AD-�6�6� which also inhi�its acid cerami-
dase activity� induces apoptosis in T�U-Pr� prostate 
cancer cells and xenograft models [���].
�trategies to prevent meta�olism of ceramide into 
complex sphingolipids have primarily focused on glu-
cosylceramide synthase �GC��. Inhi�ition of GC� 
may result in a two-pronged effect of maintaining 
intracellular ceramide while also inhi�iting the multi-
drug resistance gene MDR� or P-glycoprotein �P-gp� 
to prevent drug efflux from the cell. For instance� the 
mixed �ack�one oligonucleotide designed against 
GC� �MBO-asGC�� sensitized multi-drug resistant 
NCI/ADR-RE� xenografts to doxoru�icin �y increas-
ing C�8-cer [���] and also reduced P-gp induced drug 
efflux in tumors [���]. GC� inhi�ition coupled with Bcr-
A�l inhi�ition has also proven effective against primary 
cells isolated from T��5� mutant CML patients [���].
Ceramide and its analogs
�hort chain ceramides such as C6-cer have also �een 
com�ined with inhi�itors of phosphatidylinositol �-kinase 
[��5]� the acid ceramidase inhi�itor DM��� [��6]� HDAC 
inhi�itors [��7]� and doxoru�icin [��8] to enhance cancer 
cell apoptosis. Delivery of short chain ceramides can 
�e enhanced using transferrin liposomes that ena�le 
lysosomal internalization of ceramide resulting in ca-
thepsin mediated apoptosis of A�78� ovarian carcinoma 
cells in vitro and in vivo [��9]. Another strategy to use 
short chain ceramide therapeutically is incorporation 
of the lipid into pegylated nanoliposomes [�������]. 
Finally� analogs that mimic the function of ceramide 
can also facilitate apoptosis. For example� com�ination 
of LCL�� with photodynamic therapy induces apoptosis 
in �CCVII mouse squamous carcinoma cells [���] while 
LCL�9� a mitochondrion-targeted ceramide analog 
Table. Overview of therapeutic strategies to induce apoptosis by sphingolipid modulation
Therapeutic Approach Enzyme Model System Reference
(A) Curcumin SPT Colon cancer cells [101]
γ-Tocopherol CerS Androgen sensitive prostate cancer cells [102]
Fenretinide (4-HPR) SPT/CerS HL60 acute myeloid leukemia cells (AML), MCF7 multi-drug resistant breast cancer cells, 
HT29 colon cancer cells
[103, 104]
Cannabinoids CerS Prostate, colon, cervical, lung and pancreatic cells as well as in vivo models of prostate and 
pancreatic cancer 
[105–108]
Carbonic anhydrase 
inhibitors
CerS CA IX-positive HeLa and 786-O cells and CA IX-negative 786-O/von Hippel-Lindau (VHL) cells [109]
Ursolic acid CerS T24 bladder cancer cells [110]
Celecoxib CerS6 Colon cancer cells and xenografts [111]
(B) MDA7/IL-24 ASM/CerS6 Renal and prostate cancer cells [93, 123, 124]
Radiation ASM/CerS Endothelial cells, Jurkat T cells, HeLa cells, MCF7 cells [4, 39, 43, 115]
Cisplatin ASM HT29 colon cancer cells [40]
20-S-camptothecin 
lactone
ASM U-937 lymphoma cells [87]
Evodiamine ASM/NSM SGC-7901 gastric cancer cells [119]
Capsaicin NSM PC3 prostate cancer cells [120]
EGCG ASM Multiple myeloma cells and xenograft model [44]
α-TEA ASM MDA-MB-231 breast cancer cells and xenograft models [121]
Cyclopamine NSM Daoy medullobastoma cells [122]
(C) B13 AC Colon cancer cells and xenografts [125]
LCL204 AC Prostate and head and neck cells and xenografts [129, 130]
AD-2646 AC TSU-Pr1 prostate cancer cells and xenografts* [131]
MBO-asGCS GCS Drug resistance breast, ovary, cervical and colon cancer cells and breast xenografts [132, 133]
PDMP GCS CML — T3151 mutant cells, in vivo transplants, primary cells from T3151 patients [134]
(D) C6-cer in combination Ovarian, breast, pancreatic, melanoma cell lines and pancreatic and ovarian xenografts [135–138]
C6/C16-cer transfer-
rin liposomes
Ovarian cancer cells and xenografts [139]
C6-cer nanoliposomes Pancreatic and hepatocellular carcinoma cells and xenografts, sygeneic model of leukemia [140–143]
LCL29 MCF7 breast cancer cells [145]
LCL30 SCCVII mouse squamous carcinoma cells [144]
(E) FTY720 SK1 Hormone refractory prostate cancer cells and PC3 xenografts [146, 147]
ABC294640 SK2 Multiple cells lines and breast cancer xenografts [148, 149]
SK I-II SK1, SK2 Breast cancer cells [150]
Sonepcizumab Clinical trial including various solid malignancies [151, 152]
 (A) Stimulation of ceramide synthesis. (B) Hydrolysis of sphingomyelin. (C) Inhibition of ceramide utilization. (D) Direct use of ceramide and ceramide ana-
logs. (E) Inhibition of S1P signaling. Abbreviations used: SPT — serine palmitoyl-CoA transferase, CerS — ceramide synthase, ASM — acid sphingomyelin-
ase, NSM — neutral sphingomyelinase, AC — acid ceramidase, GCS — glucosylceramide transferase, SK — sphingosine kinase. *Although TsuPr1 was ini-
tially described as a prostate cancer cell line, it was later shown to be a derivative of T24 bladder cancer cells.
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induces Bid-independent apoptosis in MCF7 �reast 
cancer cells [��5].
Inhibition of S1P signaling
The ceramide meta�olite sphingosine serves 
as a su�strate for sphingosine kinases� which gener-
ate ��P� there�y shifting the sphingolipid rheostat 
away from apoptosis �Fig. ��. Interfering with �K or its 
product ��P is an effective therapeutic strategy [��6]. 
For example� the sphingosine analog FTY7��� which 
affects several targets within the sphingolipid net-
work� was shown to inhi�it �K� in prostate cancer 
cells and sensitized orthotopic prostate tumors 
to radiation [��7]. The orally �ioavaila�le �K� in-
hi�itor ABC�9�6�� induced apoptosis in endocrine 
therapy-resistant MDA-MB-��� and chemoresistant 
MCF-7TN-R cells� and reduced tumor volume in pre-
clinical models [��8� ��9]. �imultaneous inhi�ition 
of �oth �K isoforms �y the �KI-II inhi�itor induced 
apoptosis in multi-drug resistant �reast cancer cells 
[�5�]. Lastly� given the complexity of sphingolipid 
signaling� it is remarka�le that a monoclonal anti�ody 
against ��P known as �onepcizuma� yielded promi-
sing results against several solid tumors in Phase 
I clinical trials and is now entering Phase II trials [�5�� 
�5�]. However� whether the efficacy of �onepcizuma� 
is primarily mediated through induction of apoptosis 
or through inhi�ition of ��P-mediated inflammation 
and angiogenesis may �e difficult to determine.
CONCLUSION
Inducing apoptosis via modulation of sphingolipid me-
ta�olism is a via�le therapeutic strategy. As shown in Fig. �� 
depending on the su�cellular location of ceramide gen-
eration� apoptosis may �e facilitated through events like 
formation of ceramide-enriched platforms in the plasma 
mem�rane� permea�ilization of the outer mitochondrial 
mem�rane or other less well-defined mechanisms.
Fig. 2. Contri�ution of sphingolipids towards apoptotic signaling. 
Ceramide generated that the plasma mem�rane� mitochondria� 
lysosomes and nucleus may �e required to enhance or promote 
the apoptotic signal. Details are descri�ed in the text. Abbrevia-
tions used: �Mase — sphingomyelinase� A�M — acid sphingo-
myelinase� A�M-P — phosphorylated acid sphingomyelinase� 
�M — sphingomyelin� Cer — ceramide� �ph — sphingosine� 
Cer� — ceramide synthase� DE� — desaturase� dh�ph — dihydro-
sphingosine� dhcer — dihydroceramide� �M� — sphingomyelin 
synthase� MTMP — mitochondrial permea�ility transition pore� 
ER — endoplasmic reticulum� NPC — nuclear pore complex
Generation of ceramide can occur in a tissue- and 
stimulus-dependent manner. Therefore� it will �e impor-
tant to further elucidate the physiological roles of ce-
ramides with specific chain lengths and the contri�ution 
of specific su�cellular pools of sphingolipids towards 
apoptosis in order to develop optimally designed 
therapeutic strategies to target various types of cancer.
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